2例吡非尼酮治疗新型冠状病毒肺炎后肺纤维化的疗效分析

doi:10.13418/j.issn.1001-165x.2024.3.15

Abstract

Abstract: Objective To observe and analyze the therapeutic effect of pirfenidone on pulmonary interstitial fibrosis secondary to COVID-19. Methods Clinical data of 2 patients with pulmonary interstitial fibrosis after severe COVID-19 were collected and followed up after discharged from our hospital, and the therapeutic effect of pirfenidone on anti-fibrosis secondary to COVID-19 was analyzed. Results After the two patients were treated with pirfenidone for 15 weeks and 9 weeks respectively, dynamic review of chest CT showed that the degree of pulmonary fibrosis in both patients was significantly reduced. Conclusions Pirfenidone may be effective in improving pulmonary fibrosis after COVID-19, but it still needs to be confirmed by longer duration of follow-up and clinical studies with more samples.

Key words: Novel coronavirus 2019; , , Coronavirus disease 2019; , , Pulmonary fibrosis; , , Pirfenidone

CLC Number:

R563.1

Wang Xia, Li Jiayi, Lu Huifen, Cui Haiyan. Effect of pirfenidone on pulmonary interstitial fibrosis after COVID-19 in 2 cases[J]. Chinese Journal of Clinical Anatomy, 2024, 42(3): 331-335.

References

[1] Fabbri L, Moss S, Khan FA, et al. Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis[J]. Thorax, 2023,78(2):191-201. DOI: 10.1136/thoraxjnl-2021-218275.
[2] Remmelink M, De Mendonça R, D'Haene N, et al. Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients[J]. Crit Care, 2020, 24(1): 495. DOI: 10.1186/s13054-020-03218-5.
[3] Hirawat R, Jain N, Aslam SM, et al. Lung fibrosis: Post-COVID-19 complications and evidences[J]. Int Immunopharmacol, 2023,116:109418. DOI: 10.1016/j.intimp.2022.109418.
[4] Boshra MS, Abou WA, Sayed MA, et al. Effect of Pirfenidone on Risk of Pulmonary Fibrosis in COVID-19 Patients Experiencing Cytokine Storm[J]. Healthcare (Basel), 2022,10(12). DOI: 10.3390/healthcare10122387.
[5] Zhou X, Yang D, Kong X, et al. Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis[J]. Front Med (Lausanne), 2022,9:925703. DOI: 10.3389/fmed.2022.925703.
[6] John AE, Joseph C, Jenkins G, et al. COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts[J]. Immunol Rev, 2021,302(1):228-240. DOI: 10.1111/imr.12977.
[7] Zhang C, Wu Z, Li JW, et al. Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19[J]. J Med Virol, 2021,93(3):1378-1386. DOI: 10.1002/jmv.26634.
[8] Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study[J]. Lancet Infect Dis, 2020,20(10):1135-1140. DOI: 10.1016/S1473-3099(20)30434-5.
[9] Kerget B, Çil G, Araz Ö, et al. Comparison of two antifibrotic treatments for lung fibrosis in post-COVID-19 syndrome: A randomized, prospective study[J]. Med Clin (Barc), 2023,160(12):525-530. DOI: 10.1016/j.medcli.2022.12.021.
[10]Lancaster LH, de Andrade JA, Zibrak JD, et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis[J]. Eur Respir Rev, 2017, 26(146). DOI: 10.1183/16000617.0057-2017.
[11]中华人民共和国国家卫生健康委员会. 新型冠状病毒感染诊疗方案(试行第十版)[J]. 中华临床感染病杂志, 2023(1):1-9. DOI: 10.3760/cma.j.issn.1674-2397.2023.01.001
[12]Sansores RH, Ramírez-Venegas A, Montiel-Lopez F, et al. Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy[J]. Respir Med, 2023, 217:107362. DOI: 10.1016/j.rmed.2023.107362.
[13]Bocchino M, Rea G, Capitelli L, et al. Chest CT Lung Abnormalities 1 Year after COVID-19: A Systematic Review and Meta-Analysis[J]. Radiology, 2023, 308(1): e230535. DOI: 10.1148/radiol.230535.
[14]Al-Kuraishy HM, Batiha GE, Faidah H, et al. Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals[J]. Inflammopharmacology, 2022,30(6):2017-2026. DOI: 10.1007/s10787-022-01027-6.
[15]Kayarat B, Khanna P, Sarkar S. Pulmonary Fibrosis in COVID-19 Recovered Patients: Problem and Potential Management[J]. Indian J Crit Care Med, 2021,25(2):242-244. DOI: 10.5005/jp-journals-10071-23733.
[16]Ferrara F, Granata G, Pelliccia C, et al. The added value of pirfenidone to fight inflammation andfibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?[J]. Eur J Clin Pharmacol, 2020,76(11):1615-1618. DOI: 10.1007/s00228-020-02947-4.
[17]George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy[J]. Lancet Respir Med, 2020,8(8):807-815. DOI: 10.1016/S2213-2600(20)30225-3.

Effect of pirfenidone on pulmonary interstitial fibrosis after COVID-19 in 2 cases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	Li Haiyan, Liu Yingdong, Song Dongshuai, Yang Zhipeng, Du Xinru. Morphological observation of the communicating branches between accessory nerve, vagus nerve and cervical nerve roots and its clinical significance [J]. Chinese Journal of Clinical Anatomy, 2024, 42(3): 241-245.
[2]	Sun Ke, Zhou Guangwen, Jiang Zhiye, Wang Honggang. Basic anatomical study of percutaneous pedicle screws in transverse process root approach [J]. Chinese Journal of Clinical Anatomy, 2024, 42(3): 246-250.
[3]	Lai Wenhua, Mao Longkun, Wang Shiyu, Li Yixuan, Liu Ruiping, Xu Dazheng, Li Mingzhe, Zhou Lihua. Clinical application of celiac trunk typing variants in adults of South China [J]. Chinese Journal of Clinical Anatomy, 2024, 42(3): 259-264.
[4]	Li Yunlun, Xu Yizhou, Cai Jiale, Xu Shuyi, Zhang Jiaqi, Fu Lanya, Ma Xinrui, He Ye, Wang Xianghai, Guo Jiasong. Clodronate liposome alleviates functional regeneration after peripheral nerve injury via depleting macrophages [J]. Chinese Journal of Clinical Anatomy, 2024, 42(3): 265-269.
[5]	Que Songnian, Tu Jingdian, Han Shangfeng, Xiong Hang, Song Haiwang, Huang Tao. Effects of Angelica Sinensis Polysaccharide on modulating the gut microbiome in mice subjected to cerebral ischemia-reperfusion injury [J]. Chinese Journal of Clinical Anatomy, 2024, 42(3): 270-277.
[6]	Yang Lifang, Yu Chunze, Zhang Xianjun, Wu Chunyun, Yu Jianyun, Yang Li. Inhibition effects of cannabidiol on inflammatory response following multiple cerebral concussions in rats [J]. Chinese Journal of Clinical Anatomy, 2024, 42(3): 278-283.
[7]	Jing Xing, Shi Jinxing, Xu Dan, Zhuang Yuehong, Xie Yun, Wang Hai. Fasudil promotes axon and myelin regeneration and functional recovery after sciatic nerve injury in rats [J]. Chinese Journal of Clinical Anatomy, 2024, 42(3): 284-292.
[8]	Zhang Bihuan, Cai Xingbo, Wang Bin, Zhang Yue, Xu Yongqing. Establishment and biomechanical analysis of finite element model after partial replacement prosthesis of titanium alloy scaphoid with personalized 3D printing [J]. Chinese Journal of Clinical Anatomy, 2024, 42(3): 293-303.
[9]	Qi Baochuang, Cai Xingbo, Song Muguo, Meng Chen, Luo Huan, Li Chuan, Xu Yongqing. Clinical efficacy of four-corner arthrodesis concentrator of nickel-titanium memory alloy for carpal collapse: 9-10 years of follow-up [J]. Chinese Journal of Clinical Anatomy, 2024, 42(3): 304-309.
[10]	Liu Weixiang, Wu Yupeng, Xia Chao, Gong Yonghao, Gao Yiqiang, Yao Nvzhao. Short-term clinical efficacy of unilateral piportal endoscopic technique in the treatment of adjacent segment disease after posterior lumbar interbody fusion [J]. Chinese Journal of Clinical Anatomy, 2024, 42(3): 310-315.
[11]	Sun Shengxuan, Xie Ye, Shen Guangsi, Zhou Haibin. Clinical effect of “Chinese way” for arthroscopic treatment of shoulder dislocation combined with massive rotator cuff tear in the elderly [J]. Chinese Journal of Clinical Anatomy, 2024, 42(3): 316-321.
[12]	Zou Yang, Liu Jialong, Jin Yiyi, Li Ninglei, Sun Jingbo, Liu Xiaolong. Application of the three-step method of full laryngeal recurrent nerve visualization in laparoscopic thyroidectomy via anterior chest approach [J]. Chinese Journal of Clinical Anatomy, 2024, 42(3): 322-325.
[13]	Hu Hao, Zhou Lihua, Lv Guoyi. Comparative analysis of CT 3D reconstruction of chondroblastoma and primary aneurysmal bone cyst [J]. Chinese Journal of Clinical Anatomy, 2024, 42(3): 326-330.
[14]	Yan Zi, Li Shiyu, Wang Yilin, Wu Yaobin, Li Yanbing, Huang Wenhua. Research progress of 3D-printed articular cartilage scaffolds [J]. Chinese Journal of Clinical Anatomy, 2024, 42(3): 341-346.
[15]	Lou Yuanda, Yuan Shuai, Lin Rong, Yao Liwei, Mao Haijiao. Anatomical research progress of posterior tibial tendon [J]. Chinese Journal of Clinical Anatomy, 2024, 42(3): 347-349.